Bromfenac Sodium
Brand name: Prolensa
Rank #289 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$40.8M
Total Cost
121,284
Total Claims
$40.8M
Total Cost
2,024
Prescribers
$336
Cost per Claim
65,070
Beneficiaries
152,037
30-Day Fills
$20K
Avg Cost/Provider
60
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$40.8M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $40.8M total
Top Prescribers of Bromfenac Sodium
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Bingjing Roberts | Ophthalmology | New York, NY | 2,417 | $882K |
| 2 | Triet Nguyen | Ophthalmology | Westminster, CA | 1,453 | $553K |
| 3 | Richard Weise | Ophthalmology | Glendale, CA | 1,053 | $440K |
| 4 | Ilona Genis | Ophthalmology | Brooklyn, NY | 1,143 | $427K |
| 5 | Gang Hu | Ophthalmology | Hurst, TX | 1,017 | $364K |
| 6 | Eddie Kadrmas | Ophthalmology | Plymouth, MA | 575 | $321K |
| 7 | Triet Nguyen | Ophthalmology | Westminster, CA | 910 | $287K |
| 8 | Jacqueline Dauhajre | Ophthalmology | Jackson Heights, NY | 686 | $250K |
| 9 | Charles Gold | Optometry | New York, NY | 655 | $240K |
| 10 | Shann Lin | Ophthalmology | Pottsville, PA | 691 | $222K |
| 11 | David De Rose | Ophthalmology | Allentown, PA | 628 | $221K |
| 12 | Mitchell Shultz | Ophthalmology | Northridge, CA | 525 | $193K |
| 13 | Mario Di Pascuale | Ophthalmology | El Paso, TX | 530 | $192K |
| 14 | William Gannon | Ophthalmology | Dothan, AL | 479 | $170K |
| 15 | Michael Pisacano | Ophthalmology | Bronx, NY | 460 | $166K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 286 | Alendronate Sodium (Alendronate Sodium) | $41.4M | 3,414,824 |
| 287 | Daptomycin (Daptomycin) | $41.2M | 41,245 |
| 288 | Pitavastatin Calcium (Livalo) | $40.8M | 69,636 |
| 289 | Bromfenac Sodium (Prolensa) | $40.8M | 121,284 |
| 290 | Suvorexant (Belsomra) | $40.7M | 87,327 |
| 291 | Atogepant (Qulipta) | $40.7M | 32,955 |
| 292 | Obeticholic Acid (Ocaliva) | $40.6M | 4,131 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology